Severe metabolic accumulation of VV116 in kidney transplant patients with impaired renal function: a case series report

Frontiers in Immunology, Год журнала: 2025, Номер 15

Опубликована: Янв. 17, 2025

The treatment of COVID-19 in the post-transplant individuals is challenging, primarily due to drug-drug interaction between nirmatrelvir/ritonavir and tacrolimus. Deuremidevir hydrobromide tablets (VV116) an orally small molecule agents target SARS-CoV-2 RdRp inhibits viral replication. It may have a low likelihood interactions has potential provide new option. We described three cases renal transplant patients with concomitant impaired function who developed pneumonia were treated VV116. Despite varying degrees drug accumulation, these achieved rapid clearance showed prompt improvement symptoms. Notably, tacrolimus blood concentrations remained within therapeutic range throughout treatment, no clinically significant adverse events observed despite accumulation.

Язык: Английский

---

COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches

Cell Communication and Signaling, Год журнала: 2024, Номер 22(1)

Опубликована: Фев. 15, 2024

Abstract Extensive research in countries with high sociodemographic indices (SDIs) to date has shown that coronavirus disease 2019 (COVID-19) may be directly associated more severe outcomes among patients living haematological disorders and malignancies (HDMs). Because individuals moderate immunodeficiency are likely undergo persistent infections, shed virus particles for prolonged periods, lack an inflammatory or abortive phase, this represents overall risk of morbidity mortality from COVID-19. In cases suffering HDMs, further investigation is needed achieve a better understanding triviruses group related variants anemia as well their treatment through vaccines, drugs, other methods. Against background, the present study aimed delineate relationship between HDMs novel COVID-19, acute respiratory syndrome 2 (SARS-CoV-2). Besides, effective options HDM were explored address epidemic its variants. Therefore, learning about how COVID-19 manifests these patients, along exploiting most appropriate treatments, lead development care strategies by clinicians researchers help recover faster.

Язык: Английский

---

Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review

Life, Год журнала: 2024, Номер 14(2), С. 214 - 214

Опубликована: Фев. 1, 2024

Since late 2019, the new SARS-CoV-2 virus belonging to Coronaviridae family has been responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral therapies, mostly derived from previous epidemics, were initially repurposed fight this not rarely life-threatening illness. Among them, however, only specific antibody-based therapy available against infection during first year of pandemic was represented by convalescent plasma (CCP). CCP, collected recovered individuals, contains high levels polyclonal antibodies different subclasses able neutralize infection. Tens randomized controlled trials have conducted last three years evaluate safety and clinical efficacy CCP in both hospitalized ambulatory patients, whose main results will be summarized narrative review. In addition, we present current knowledge on development anti-SARS-CoV-2 hyperimmune immunoglobulins.

Язык: Английский

---

Hyperimmune Plasma and Immunoglobulins Against COVID-19: A Narrative Review

Опубликована: Ноя. 22, 2023

Since late 2019, COVID-19, a severe acute respiratory syndrome pandemic, was caused by the new SARS-CoV-2 virus belonging to Coronaviridae family, . Several antiviral therapies, mostly derived from previous epidemics, were initially repurposed fight this not rarely life-threatening illness. Among them, however, only specific antibody-based therapy available against infection during first year of pandemic represented COVID-19 convalescent plasma (CCP). CCP, collected recovered individuals, contains high levels polyclonal antibodies different subclasses able neutralize infection. Tens randomized controlled trials have been conducted last three years evaluate safety and clinical efficacy CCP in both hospitalized ambulatory patients, whose main results will be summarized narrative review. In addition, we present current knowledge on development anti-SARS-CoV-2 hyperimmune immunoglobulins.

Язык: Английский

---

Investigating the Impact of COVID-19 on the Incidence of Cardiovascular Diseases: A Cross-sectional Study

The Open Public Health Journal, Год журнала: 2024, Номер 17(1)

Опубликована: Июнь 21, 2024

Background The inflammation caused by COVID-19 can cause blood clots, block the heart vessels and lead to attack. Aim This study aims toinvestigate impact of on diseases in patients referred Imam Khomeini Hospital Jiroft City. Methods is a cross-sectional (descriptive-analytical) study. statistical population includes all cardiovascular who visited two years before Corona (March 2017 March 2019) after 2019 2021). Data were analyzed using SPSS software version 20. chi-square test was used investigate relationship between qualitative variables groups. level significance this considered less than 0.05. Results average age 60.02 ± 16.7 years, during 63.9 16.8 group 1, 50.5% men, 2, 51% women. has 14.2% increase diseases. Acute coronary syndrome, attacks, failure increased 11.3%, 32.2%, 9.5%, respectively, COVID-19pandemic compared pandemic. Conclusion Based findings study, special attention should be paid support these specific diagnostic treatment protocols developed prevent complications treat with COVID-19.

Язык: Английский

---

COVID-19 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): a propensity matched analysis (2020-2021)

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Окт. 17, 2024

By 2023, COVID-19 had caused 6.8 million deaths in the United States. presents more severely leukemia compared to solid tumors (OR 1.6, p<0.05). However, data on Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) are limited. We investigated mortality AML MDS patients with COVID-19.

Язык: Английский

---

Outcomes and Risk Factors in Patients with Hematologic Malignancies Following Late-Stage SARS-CoV-2 Infection

Journal of Multidisciplinary Healthcare, Год журнала: 2024, Номер Volume 17, С. 5853 - 5865

Опубликована: Дек. 1, 2024

To investigate the outcomes and risk factors for patients with hematologic malignancies (HM) following late-stage SARS-CoV-2 infection.

Язык: Английский

---